THE WOODLANDS, TEXAS, DEC. 20, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for…Original Article
Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin)
